October 25, 2016

FASTER, PLEASE: Pembrolizumab Approved in US for First Line in NSCLC. “After causing a sensation at the recent European Society for Medical Oncology (ESMO) meeting, the new data for pembrolizumab (Keytruda, Merck & Co) in the first-line treatment of non-small cell lung cancer (NSCLC) have now secured an approval from the US Food and Drug Administration (FDA). Pembrolizumab is now the first immunotherapy to be approved for first-line use in NSCLC and is expected to change practice, experts said at the meeting. . . . The approval for the new indication is based on results showing that pembrolizumab was superior to chemotherapy in the first-line setting.”

InstaPundit is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.